Prostate cancer therapy - DebiopharmAlternative Names: E2 agonist/GnRH agonist - Debiopharm; Estrogen agonist/gonadotrophin releasing hormone agonist - Debiopharm; GnRH agonist/E2 agonist - Debiopharm; Gonadotrophin releasing hormone agonist/estrogen agonist - Debiopharm; TRIO; TRIO - Debiopharm
Latest Information Update: 12 Aug 2010
At a glance
- Originator Debiopharm
- Class Hormones
- Mechanism of Action Estrogen receptor agonists; Gonadotropin releasing hormone stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 05 Sep 2005 Phase-I/II clinical trials in Prostate cancer in Europe (unspecified route)